Weekly Recap | AKESO +12.57%, ivonescimab hits survival endpointWeekly Review·Sep 5 at 05:56 AM09926-1.75%
Weekly Recap | AKESO +7.92%, ivonescimab Phase III hits endpointWeekly Review·Aug 29 at 05:06 AM09926-1.75%
Weekly Recap | AKESO -0.28%, new drug progress fuels swingsWeekly Review·Aug 22 at 04:29 AM09926-1.75%